Recite me link

Q1. In the last 3 months, how many patients have been initiated* on the following agents for the treatment of melanoma?
a. Ipilimumab (monotherapy)
b. Nivolumab (monotherapy)
c. Nivolumab AND Ipilimumab (combination)
d. Pembrolizumab
e. Any Targeted Therapy (Dabrafenib /Dabrafenib AND Trametinib /Encorafenib AND Binimetinib /Trametinib /Vemurafenib /Vemurafenib AND Cobimetinib)
f. Other active systemic anti-cancer therapy
*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.

Q2. In the last 3 months, how many patients have been initiated* on the following agents for the treatment of renal cell carcinoma?
a. Nivolumab (monotherapy)
b. Nivolumab + Ipilimumab
c. Nivolumab + Cabozantinib
d. Avelumab + Axitinib
*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.

Q3. In the past 3 months, how many patients have been initiated* on the following agents for the treatment of gastric, gastro-oesophageal junction or oesophageal cancer:
a. Nivolumab monotherapy or in combination with Ipilimumab
b. Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidene (5-Fluorouracil or Capecitabine)
c. Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidene (5-Fluorouracil or Capecitabine)
*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.

Nivolumab.020823.docx